+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method



Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method



Bmc Cancer 16: 454



Label="BACKGROUND">The PIK3CA (H1047R) mutation is considered to be a potential predictive biomarker for EGFR-targeted therapies. In this study, we developed a novel PCR-PFLP approach to detect the PIK3CA (H1047R) mutation in high effectiveness.Label="METHODS">A 126-bp fragment of PIK3CA exon-20 was amplified by PCR, digested with FspI restriction endonuclease and separated by 3 % agarose gel electrophoresis for the PCR-RFLP analysis. The mutant sequence of the PIK3CA (H1047R) was spiked into the corresponding wild-type sequence in decreasing ratios for sensitivity analysis. Eight-six cases of formalin-fixed paraffin-embedded colorectal cancer (CRC) specimens were subjected to PCR-RFLP to evaluate the applicability of the method.Label="RESULTS">The PCR-RFLP method had a capability to detect as litter as 0.4 % of mutation, and revealed 16.3 % of the PIK3CA (H1047R) mutation in 86 CRC tissues, which was significantly higher than that discovered by DNA sequencing (9.3 %). A positive association between the PIK3CA (H1047R) mutation and the patients' age was first found, except for the negative relationship with the degree of tumor differentiation. In addition, the highly sensitive detection of a combinatorial mutation of PIK3CA, KRAS and BRAF was achieved using individual PCR-RFLP methods.Label="CONCLUSIONS">We developed a sensitive, simple and rapid approach to detect the low-abundance PIK3CA (H1047R) mutation in real CRC specimens, providing an effective tool for guiding cancer targeted therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057998660

Download citation: RISBibTeXText

PMID: 27405731

DOI: 10.1186/s12885-016-2493-9


Related references

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Science 109(8): 2558-2566, 2018

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget 4(9): 1484-1495, 2013

PIK3CA H1047R -induced paradoxical ERK activation results in resistance to BRAF V600E specific inhibitors in BRAF V600E PIK3CA H1047R double mutant thyroid tumors. Oncotarget 8(61): 103207-103222, 2017

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Bmc Cancer 19(1): 442, 2019

PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. Journal of Molecular Diagnostics 12(5): 697-704, 2010

PI3K/mTOR Inhibitors in Cancers with PIK3CA H1047R Mutation. 2013

A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. International Journal of Cancer 85(1): 73-77, 2000

A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. International Journal of Cancer 85(1): 73-77, 2000

A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients. Anticancer Research 27(3b): 1459-1463, 2007

Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. Molecular Diagnosis and Therapy 21(4): 443-451, 2017

Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method. Plos one 12(2): E0171225, 2017

Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Developmental Biology 404(1): 14-26, 2015

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Research 73(1): 276-284, 2013

Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. Plos one 7(5): E36924, 2012

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochemical Journal 458(2): 251-258, 2014